BCL2 and axial length measurement: As this was a small retrospective reported series in which venetoclax was used in varying therapy combinations, it is difficult to generalize when speaking of response rates, though ongoing planned studies of venetoclax and other BCL-2 targeted agents are planned in both previously treated and newly diagnosed AL harboring t(11;14).